Fig. 5: Colonogenic potentials and drug combination strategies in p190 and p210 cell lines. | Leukemia

Fig. 5: Colonogenic potentials and drug combination strategies in p190 and p210 cell lines.

From: Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets

Fig. 5

a Number of colonies produced by p190-HPC-LSK and p210-HPC-LSK cell lines. b Density plot showing phenotypic analysis of harvested cells from p190-HPC-LSK and p210-HPC-LSK colonies using flowcytometry. CD19 (lymphoid marker) on vertical axis and CD11b (granulocytic marker) on horizontal axis. c Comparison of the inhibitory effect of imatinib, dasatinib, LCL161, dexamethasone, FRAX486, idasanutlin, and IFNα on colonogenic potentials of p190-HPC-LSK and p210-HPC-LSK. Bar height indicate the average colony counts (normalized to respective control condition) and error bars represent standard deviation. Dose response curves of percent inhibition achieved with imatinib alone and in combination with indicated concentrations of LCL161, FRAX486, idasanutlin, dexamethazone, and IFNα in (d) p190-Ba/f3 and (e) p190-HPC-LSK cell lines. The experiments were conducted in triplicates. f Comparison of the inhibitory effect of imatinib (100 nM) alone and in combination with the indicated concentrations of LCL161, FRAX486, idasanutlin, dexamethazone, and IFNα on the colonogenic potentials of p190-HPC-LSK cells. (*) means p < 0.05, (**) means p < 0.01, (***) means p < 0.001, and (****) means p < 0.0001.

Back to article page